ZEPOSIA® (ozanimod) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
It is not known if ZEPOSIA is safe and effective in children.
ZEPOSIA® (ozanimod) is a prescription medicine used to treat moderately to severely active ulcerative colitis (UC) in adults.
It is not known if ZEPOSIA is safe and effective in children.
Step
4Getting ZEPOSIA delivered
These steps will begin once your Start Form (your ZEPOSIA prescription) is submitted to ZEPOSIA 360 Support™.
Step
1
As your dedicated point of contact for all things ZEPOSIA, your
MS Nurse Navigator will call you to get things started.
Consider adding this number to your phone so you can identify the call:
They can help in a number of ways, including:
If you haven’t heard from your Nurse Navigator, reach out to your healthcare team to ensure that your Start Form was submitted to ZEPOSIA 360 Support.
This type of insurance is usually provided by an employer or a union, or purchased directly from an insurance company.
Step
2
Before you start taking ZEPOSIA, two routine tests are required. If you have a history of certain eye conditions (macular edema or uveitis) you may also need an eye exam. Let your healthcare team know if you’ve had some of these tests within the last six months—they may not need to be repeated:
Blood work—including complete blood count and liver function test.
These tests can be completed at your home, if you’re eligible.§ Your MS Nurse Navigator can help schedule them
Any potential out-of-pocket costs may be reimbursed. There may be costs associated with some of the routine medical tests, but depending on where these tests take place, eligible patients may qualify for reimbursement or incur no costs at all†
Step
3
Once you've been approved to begin treatment, you'll receive the ZEPOSIA Starter Kit. It will either be provided to you by your MS healthcare team or delivered directly to your home.
The ZEPOSIA Starter Kit includes medication for the first 37 days of treatment and has two parts:
A 7-day Starter Pack, which increases your dosage gradually. Each capsule is labeled by day and color coded by dosage size. You’ll take one capsule each day.
A 30-day supply, which you’ll begin taking on day 8 (after completing the 7-day Starter Pack). These orange capsules are the regular daily dosage (0.92 mg) of ZEPOSIA.
Step
4
A specialty pharmacy is different from a regular retail pharmacy. It distributes medications for certain chronic conditions and delivers them directly to you. Some specialty pharmacies also offer in-store pick up.
My MS Nurse Navigator coordinated with my specialty pharmacy to arrange delivery of ZEPOSIA directly to my home, which works great for me.”
—Omar
A real ZEPOSIA patient compensated for his time.
Those who are eligible may pay as little as $0 a month for ZEPOSIA with a co-pay savings offer.†
Sign up for ZEPOSIA 360 Support™ to receive resources, information, and support for starting and staying on treatment.
*The Bridge Program is available at no cost for eligible, commercially insured, on-label diagnosed patients if there is a delay in determining whether commercial prescription coverage is available, and is not contingent on any purchase requirement, for up to 24 months (dispensed in 30-day increments). The Bridge Program is not available to patients who have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPUS, TRICARE, Veterans Affairs (VA), or Department of Defense (DoD) programs and is available for no more than 12 months to patients in MA, MN, and RI. Appeal of any prior authorization denial must be made within 90 days or as per payer guidelines, to remain in the program. Eligibility will be re-verified in January for patients continuing into the following year, and may be at other times during program participation. Offer is not health insurance. Once coverage is approved by the patient’s commercial insurance plan, the patient will no longer be eligible. Void where prohibited by law, taxed, or restricted. Bristol-Myers Squibb Company reserves the right to rescind, revoke, or amend this program at any time without notice. Other limitations may apply.
†ZEPOSIA Co-pay Program is valid only for patients with commercial insurance. The Program includes a prescription benefit offer for out-of-pocket drug costs and a medical assessment benefit offer for out-of-pocket costs for the initial blood tests, ECG screening, and eye exam where the full cost is not covered by patient’s insurance. Patients are not eligible for the prescription benefit offer if they have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPUS, TRICARE, Veterans Affairs (VA), or Department of Defense (DoD) programs. Patients are not eligible for the medical assessment benefit offer if they have insurance coverage for their prescription or medical assessment through a state or federal healthcare program, or reside in Massachusetts, Minnesota or Rhode Island. Patients who move from commercial plans to state or federal healthcare programs will no longer be eligible. Patient must be 18 years of age or older. Patients may pay as little as $0 in out-of-pocket costs per prescription, subject to a maximum benefit of $18,000 during a calendar year. Patients may pay as little as $0 in out-of-pocket costs for the medical assessment, subject to a maximum benefit of $2,000. The medical benefit offer only applies to clinical baseline assessment services covered by the Program. Patients are responsible for any costs that exceed the maximum amounts. To receive the medical assessment benefit, an Explanation of Benefits (EOB) form must be submitted, along with copies of receipts for any payments made. The Program expires on December 31, 2023. All Program payments are for the benefit of the patient only. Patients, pharmacists, and prescribers may not seek reimbursement from health insurance, health savings or flexible spending accounts, or any third party, for any part of the prescription or medical assessment benefit received by the patient through this Program. Patient’s acceptance of any Program benefit confirms that it is consistent with patient’s insurance and that patient will report the value received as may be required by his/her insurance provider. Program valid only in the United States and Puerto Rico. Void where prohibited by law, taxed, or restricted. The Program cannot be combined with any other offer, rebate, coupon, or free trial. The Program is not conditioned on any past, present or future purchase, including refills. The Program is not insurance. Other limitations may apply. Bristol Myers Squibb reserves the right to rescind, revoke, or amend this Program at any time without notice.
‡Data provided by Bristol Myers Squibb and is current as of December 2022.
§Patient must have a valid prescription for ZEPOSIA for an FDA-approved indication. Patient must be commercially insured. Patients are not eligible if they have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPUS, TRICARE, Veterans Affairs (VA), or Department of Defense (DoD) programs, or reside in Rhode Island. To receive the In-Home Medical Services Program, the prescriber must request in-home assessment assistance through the ZEPOSIA 360 Support program. The patient’s insurance will not be billed, and the patient will not be responsible for any out-of-pocket costs. Patients who move from commercial plans to state or federal healthcare programs will no longer be eligible. The program cannot be combined with any other offer, rebate, coupon, or free trial. The program is not conditioned on any past, present, or future purchase, including refills. Only valid in the United States and US Territories. Void where prohibited by law, taxed, or restricted. The program is not insurance. Bristol-Myers Squibb Company reserves the right to rescind, revoke, or amend this program at any time without notice. Other limitations may apply.
Collapse
–
Do not take ZEPOSIA if you:
Talk to your healthcare provider before taking ZEPOSIA if you have any of these conditions or do not know if you have any of these conditions.
ZEPOSIA may cause serious side effects, including:
Call your healthcare provider right away if you have any of these symptoms of an infection during treatment with ZEPOSIA and for 3 months after your last dose of ZEPOSIA:
Your healthcare provider may delay starting or may stop your ZEPOSIA treatment if you have an infection.
Progressive multifocal leukoencephalopathy (PML). ZEPOSIA can increase your risk for PML, which is a rare brain infection that usually leads to death or severe disability. If PML happens, it usually happens in people with weakened immune systems but has happened in people who do not have weakened immune systems. Symptoms of PML get worse over days to weeks. Call your doctor right away if you have any new or worsening symptoms of PML that have lasted several days, including: weakness on one (1) side of your body, changes in your vision, changes in your thinking or memory, confusion, changes in your personality, loss of coordination in your arms or legs, decreased strength, and/or problems with balance.
Call your healthcare provider if you experience the following symptoms of slow heart rate:
Follow directions from your healthcare provider when starting ZEPOSIA and when you miss a dose.
Continue reading for additional possible serious side effects of ZEPOSIA.
Before taking ZEPOSIA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take or have recently taken, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using ZEPOSIA with other medicines can cause serious side effects. Especially tell your healthcare provider if you take or have taken:
You should not receive live vaccines during treatment with ZEPOSIA, for at least 1 month before taking ZEPOSIA and for 3 months after you stop taking ZEPOSIA. Vaccines may not work as well when given during treatment with ZEPOSIA.
ZEPOSIA can cause serious side effects, including:
The most common side effects of ZEPOSIA can include:
These are not all of the possible side effects of ZEPOSIA. For more information, ask your healthcare provider or pharmacist.
Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Multiple Sclerosis (MS): ZEPOSIA® (ozanimod) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Ulcerative Colitis (UC): ZEPOSIA is a prescription medicine used to treat moderately to severely active ulcerative colitis (UC) in adults.
It is not known if ZEPOSIA is safe and effective in children.
Please see full Prescribing Information, including Medication Guide.
+
Do not take ZEPOSIA if you: